https://www.epigenomics.com/epigenomics-ag-heino-von-prondzynski-kauf-2/ 2022-12-19T22:00:00+00:00 https://www.epigenomics.com/epigenomics-ag-heino-von-prondzynski-buy-2/ 2022-12-19T22:00:00+00:00 https://www.epigenomics.com/de/epigenomics-ag-veroffentlichung-gemas-%c2%a7-40-abs-1-wphg-mit-dem-ziel-der-europaweiten-verbreitung-43-2/ 2022-12-20T11:12:31+00:00 https://www.epigenomics.com/%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8bepigenomics-ag-further-raise-of-earnings-guidance-for-the-current-fiscal-year-2022/ 2022-12-20T22:00:00+00:00 https://www.epigenomics.com/de/%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8bepigenomics-ag-erneute-anhebung-der-ergebnisprognose-fur-das-laufende-geschaftsjahr-2022/ 2022-12-20T22:00:00+00:00 https://www.epigenomics.com/de/epigenomics-ag-heino-von-prondzynski-buy-2/ 2022-12-21T14:24:11+00:00 https://www.epigenomics.com/de/epigenomics-ag-heino-von-prondzynski-buy/ 2022-12-21T14:24:12+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-english-8/ 2022-12-21T14:24:13+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-english-7/ 2022-12-21T14:24:17+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-english/ 2022-12-21T14:24:18+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-english-2/ 2022-12-21T14:24:23+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-english-3/ 2022-12-21T14:24:25+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-english-4/ 2022-12-21T14:24:30+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-english-5/ 2022-12-21T14:24:30+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-english-6/ 2022-12-21T14:24:37+00:00 https://www.epigenomics.com/epigenomics-ag-dr-helge-lubenow-buy/ 2022-12-21T22:00:00+00:00 https://www.epigenomics.com/de/%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8bpareto-securities-as-veroffentlicht-kaufempfehlung-fur-die-aktie-der-epigenomics-ag/ 2022-12-22T22:00:00+00:00 https://www.epigenomics.com/epigenomics-ag-heino-von-prondzynski-buy-3/ 2022-12-22T22:00:00+00:00 https://www.epigenomics.com/epigenomics-ag-jens-ravens-buy/ 2022-12-28T22:00:00+00:00 https://www.epigenomics.com/herabsetzung-des-grundkapitals-nach-den-vorschriften-uber-die-ordentliche-kapitalherabsetzung-gemas-%c2%a7-222-ff-aktg-durch-zusammenlegung-von-aktien-und-umstellung-der-borsennotierung/ 2023-01-04T17:58:52+00:00 https://www.epigenomics.com/de/epigenomics-ag-veroffentlichung-gemas-%c2%a7-40-abs-1-wphg-mit-dem-ziel-der-europaweiten-verbreitung-44/ 2023-01-23T22:00:00+00:00 https://www.epigenomics.com/epigenomics-ag-veroeffentlichung-gemaess-%c2%a7-40-abs-1-wphg-mit-dem-ziel-der-europaweiten-verbreitung/ 2023-01-24T14:04:05+00:00 https://www.epigenomics.com/de/epigenomics-ag-heino-von-prondzynski-kauf-3/ 2023-01-25T20:37:46+00:00 https://www.epigenomics.com/de/epigenomics-ag-jens-ravens-kauf/ 2023-01-25T20:37:46+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-73/ 2023-01-25T20:37:47+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-70/ 2023-01-25T20:37:47+00:00 https://www.epigenomics.com/de/epigenomics-ag-heino-von-prondzynski-kauf/ 2023-01-25T20:37:47+00:00 https://www.epigenomics.com/de/epigenomics-ag-heino-von-prondzynski-kauf-2/ 2023-01-25T20:37:47+00:00 https://www.epigenomics.com/de/epigenomics-ag-dr-helge-lubenow-kauf/ 2023-01-25T20:37:47+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-67/ 2023-01-25T20:37:48+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-68/ 2023-01-25T20:37:48+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-69/ 2023-01-25T20:37:48+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-72/ 2023-01-25T20:37:48+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-71/ 2023-01-25T20:37:48+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-62/ 2023-01-25T20:37:49+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-63/ 2023-01-25T20:37:49+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-64/ 2023-01-25T20:37:49+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-65/ 2023-01-25T20:37:49+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-66/ 2023-01-25T20:37:49+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-59/ 2023-01-25T20:37:50+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-60/ 2023-01-25T20:37:50+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-61/ 2023-01-25T20:37:50+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch/ 2023-01-25T20:37:51+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-2/ 2023-01-25T20:37:51+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-3/ 2023-01-25T20:37:52+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-4/ 2023-01-25T20:37:52+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-5/ 2023-01-25T20:37:52+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-6/ 2023-01-25T20:37:52+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-7/ 2023-01-25T20:37:52+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-11/ 2023-01-25T20:37:53+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-12/ 2023-01-25T20:37:53+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-10/ 2023-01-25T20:37:53+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-9/ 2023-01-25T20:37:53+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-8/ 2023-01-25T20:37:53+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-18/ 2023-01-25T20:37:54+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-14/ 2023-01-25T20:37:54+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-15/ 2023-01-25T20:37:54+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-16/ 2023-01-25T20:37:54+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-17/ 2023-01-25T20:37:54+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-13/ 2023-01-25T20:37:54+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-20/ 2023-01-25T20:37:55+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-19/ 2023-01-25T20:37:55+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-22/ 2023-01-25T20:37:56+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-23/ 2023-01-25T20:37:56+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-21/ 2023-01-25T20:37:56+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-29/ 2023-01-25T20:37:57+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-28/ 2023-01-25T20:37:57+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-24/ 2023-01-25T20:37:57+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-25/ 2023-01-25T20:37:57+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-26/ 2023-01-25T20:37:57+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-27/ 2023-01-25T20:37:57+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-31/ 2023-01-25T20:37:58+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-32/ 2023-01-25T20:37:58+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-33/ 2023-01-25T20:37:58+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-34/ 2023-01-25T20:37:58+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-30/ 2023-01-25T20:37:58+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-39/ 2023-01-25T20:37:59+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-36/ 2023-01-25T20:37:59+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-37/ 2023-01-25T20:37:59+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-38/ 2023-01-25T20:37:59+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-35/ 2023-01-25T20:37:59+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-40/ 2023-01-25T20:38:00+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-43/ 2023-01-25T20:38:01+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-44/ 2023-01-25T20:38:01+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-42/ 2023-01-25T20:38:01+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-41/ 2023-01-25T20:38:01+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-48/ 2023-01-25T20:38:02+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-46/ 2023-01-25T20:38:02+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-47/ 2023-01-25T20:38:02+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-45/ 2023-01-25T20:38:02+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-54/ 2023-01-25T20:38:03+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-53/ 2023-01-25T20:38:03+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-52/ 2023-01-25T20:38:03+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-50/ 2023-01-25T20:38:03+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-51/ 2023-01-25T20:38:03+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-49/ 2023-01-25T20:38:03+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-58/ 2023-01-25T20:38:04+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-57/ 2023-01-25T20:38:04+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-56/ 2023-01-25T20:38:04+00:00 https://www.epigenomics.com/de/dgap-dd-epigenomics-ag-deutsch-55/ 2023-01-25T20:38:04+00:00 https://www.epigenomics.com/de/epigenomics-ag-veroeffentlichung-gemaess-%c2%a7-40-abs-1-wphg-mit-dem-ziel-der-europaweiten-verbreitung/ 2023-01-26T20:33:55+00:00 https://www.epigenomics.com/epigenomics-ag-veroffentlichung-gemas-%c2%a7-40-abs-1-wphg-mit-dem-ziel-der-europaweiten-verbreitung-44/ 2023-01-26T20:38:17+00:00 https://www.epigenomics.com/de/epigenomics-ag-veroeffentlichung-der-gesamtzahl-der-stimmrechte-nach-%c2%a7-41-wphg-mit-dem-ziel-der-europaweiten-verbreitung/ 2023-12-06T14:00:28+00:00 https://www.epigenomics.com/epigenomics-ag-release-according-to-article-41-of-the-wphg-the-german-securities-trading-act-with-the-objective-of-europe-wide-distribution-11/ 2023-01-26T21:06:45+00:00 https://www.epigenomics.com/de/epigenomics-ag-rucktritt-des-aufsichtsratsvorsitzenden-heino-von-prondzynski/ 2023-01-26T22:00:00+00:00 https://www.epigenomics.com/de/%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8bepigenomics-ag-rucktritt-des-aufsichtsratsvorsitzenden-heino-von-prondzynski/ 2023-01-26T22:00:00+00:00 https://www.epigenomics.com/%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8bepigenomics-ag-resignation-of-the-chairman-of-the-supervisory-board-heino-von-prondzynski/ 2023-01-26T22:00:00+00:00 https://www.epigenomics.com/epigenomics-ag-resignation-of-the-chairman-of-the-supervisory-board-heino-von-prondzynski/ 2023-01-27T14:03:34+00:00 https://www.epigenomics.com/de/epigenomics-ag-veroeffentlichung-der-gesamtzahl-der-stimmrechte-nach-%c2%a7-41-wphg-mit-dem-ziel-der-europaweiten-verbreitung-2/ 2023-01-31T09:13:16+00:00 https://www.epigenomics.com/epigenomics-ag-release-according-to-article-41-of-the-wphg-the-german-securities-trading-act-with-the-objective-of-europe-wide-distribution-12/ 2023-01-31T09:17:57+00:00 https://www.epigenomics.com/de/epigenomics-ag-release-according-to-article-41-of-the-wphg-the-german-securities-trading-act-with-the-objective-of-europe-wide-distribution-6/ 2023-01-31T09:19:42+00:00 https://www.epigenomics.com/de/epigenomics-ag-veroeffentlichung-der-gesamtzahl-der-stimmrechte-nach-%c2%a7-41-wphg-mit-dem-ziel-der-europaweiten-verbreitung-3/ 2023-01-31T09:31:15+00:00 https://www.epigenomics.com/de/correction-of-a-release-from-21-05-2021-1434-cet-cest-epigenomics-ag-release-according-to-article-41-of-the-wphg-the-german-securities-trading-act-with-the-objective-of-europe-wide-distribution/ 2023-01-31T09:42:26+00:00 https://www.epigenomics.com/epigenomics-ag-release-according-to-article-41-of-the-wphg-the-german-securities-trading-act-with-the-objective-of-europe-wide-distribution-13/ 2023-01-31T09:53:45+00:00 https://www.epigenomics.com/de/epigenomics-ag-release-according-to-article-41-of-the-wphg-the-german-securities-trading-act-with-the-objective-of-europe-wide-distribution-3/ 2023-01-31T09:54:34+00:00 https://www.epigenomics.com/de/epigenomics-ag-release-according-to-article-41-of-the-wphg-the-german-securities-trading-act-with-the-objective-of-europe-wide-distribution-2/ 2023-01-31T09:56:38+00:00 https://www.epigenomics.com/de/epigenomics-ag-veroffentlichung-gemas-%c2%a7-40-abs-1-wphg-mit-dem-ziel-der-europaweiten-verbreitung-45/ 2023-02-07T22:00:00+00:00 https://www.epigenomics.com/de/%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8bepigenomics-beschliest-restrukturierung-zur-kostenminimierung/ 2023-02-14T22:00:00+00:00 https://www.epigenomics.com/de/%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8bepigenomics-beschliest-restrukturierung-zur-kostenminimierung-2/ 2023-02-14T22:00:00+00:00 https://www.epigenomics.com/%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8bepigenomics-resolves-on-restructuring-to-minimize-costs/ 2023-02-14T22:00:00+00:00 https://www.epigenomics.com/epigenomics-resolves-on-restructuring-to-minimize-costs/ 2023-02-15T10:43:11+00:00 https://www.epigenomics.com/de/epigenomics-ag-veroffentlichung-gemas-%c2%a7-40-abs-1-wphg-mit-dem-ziel-der-europaweiten-verbreitung-46/ 2023-02-26T22:00:00+00:00 https://www.epigenomics.com/de/epigenomics-ag-widerruf-der-zulassung-zum-prime-standard-teilbereich-des-regulierten-marktes-mit-weiteren-zulassungsfolgepflichten/ 2023-03-11T12:26:32+00:00 https://www.epigenomics.com/de/epigenomics-ag-%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8bprognoseanpassung-und-verlustanzeige-nach-%c2%a7-92-aktg/ 2023-03-19T22:00:00+00:00 https://www.epigenomics.com/epigenomics-ag-adjustment-of-guidance-and-notice-of-loss-pursuant-to-sec-92-para-1-of-the-german-stock-corporation-act-2/ 2023-03-19T22:00:00+00:00 https://www.epigenomics.com/epigenomics-ag-adjustment-of-guidance-and-notice-of-loss-pursuant-to-sec-92-para-1-of-the-german-stock-corporation-act/ 2023-03-20T23:13:27+00:00 https://www.epigenomics.com/de/epigenomics-ag-anderungen-in-der-geschaftsfuhrung/ 2023-04-11T23:00:00+01:00 https://www.epigenomics.com/de/epigenomics-ag-rucktritt-des-vorstandsvorsitzenden-greg-hamilton/ 2023-04-11T23:00:00+01:00 https://www.epigenomics.com/epigenomics-ag-changes-in-the-management/ 2023-04-11T23:00:00+01:00 https://www.epigenomics.com/de/epigenomics-ag-vorabbekanntmachung-ueber-die-veroeffentlichung-von-finanzberichten-gemaess-%c2%a7-114-115-117-wphg/ 2023-04-13T11:13:48+01:00 https://www.epigenomics.com/epigenomics-ag-preliminary-announcement-of-the-publication-of-financial-reports-according-to-articles-114-115-117-of-the-wphg-the-german-securities-act/ 2023-04-13T11:15:39+01:00 https://www.epigenomics.com/epigenomics-ag-release-according-to-article-41-of-the-wphg-the-german-securities-trading-act-with-the-objective-of-europe-wide-distribution-14/ 2023-04-26T12:34:14+01:00 https://www.epigenomics.com/de/epigenomics-ag-veroeffentlichung-der-gesamtzahl-der-stimmrechte-nach-%c2%a7-41-wphg-mit-dem-ziel-der-europaweiten-verbreitung-4/ 2023-04-26T12:35:08+01:00 https://www.epigenomics.com/de/%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8bepigenomics-ag-veroffentlicht-finanzergebnisse-fur-das-geschaftsjahr-2022/ 2023-04-27T23:00:00+01:00 https://www.epigenomics.com/%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8bepigenomics-ag-publishes-financial-results-for-fiscal-year-2022/ 2023-04-27T23:00:00+01:00 https://www.epigenomics.com/%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8bpareto-securities-as-publishes-buy-recommendation-for-epigenomics-ag-share/ 2023-04-28T08:03:04+01:00 https://www.epigenomics.com/epigenomics-ag-resignation-of-supervisory-board-chairman-heino-von-prondzynski/ 2023-04-28T08:03:04+01:00 https://www.epigenomics.com/%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8bepigenomics-decides-to-restructure-to-minimize-costs/ 2023-04-28T08:03:04+01:00 https://www.epigenomics.com/epigenomics-ag-revocation-of-admission-to-the-prime-standard-sub-segment-of-the-regulated-market-with-additional-post-admission-obligations/ 2023-04-28T08:03:04+01:00 https://www.epigenomics.com/epigenomics-ag-chief-executive-officer-greg-hamilton-resigns/ 2023-04-28T08:03:04+01:00 https://www.epigenomics.com/epigenomics-ag-notice-of-loss-pursuant-to-sec-92-par-1-aktg/ 2023-04-28T08:03:05+01:00 https://www.epigenomics.com/epigenomics-initiates-prospective-multi-center-clinical-trial-for-next-generation-blood-based-colorectal-cancer-test/ 2023-04-28T08:03:05+01:00 https://www.epigenomics.com/%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8bepigenomics-ag-reports-financial-results-for-the-first-nine-months-2022/ 2023-04-28T08:03:05+01:00 https://www.epigenomics.com/epigenomics-releases-performance-data-on-next-generation-test/ 2023-04-28T08:03:05+01:00 https://www.epigenomics.com/epigenomics-licenses-protein-biomarker-technology-for-blood-based-colorectal-cancer-test/ 2023-04-28T08:03:05+01:00 https://www.epigenomics.com/epigenomics-ag-publishes-financial-results-for-the-first-nine-months-2021/ 2023-04-28T08:03:06+01:00 https://www.epigenomics.com/%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8bsupervisory-board-of-epigenomics-ag-appoints-dr-andrew-lukowiak-as-president-and-chief-scientific-officer/ 2023-04-28T08:03:06+01:00 https://www.epigenomics.com/%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8bsupervisory-board-of-epigenomics-ag-appoints-jens-ravens-as-chief-financial-officer/ 2023-04-28T08:03:06+01:00 https://www.epigenomics.com/supervisory-board-of-epigenomics-ag-retains-greg-hamilton-as-chief-executive-officer-through-development-of-epi-procolon-next-gen-colorectal-cancer-screening-test/ 2023-04-28T08:03:06+01:00 https://www.epigenomics.com/%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8bepigenomics-ag-reports-financial-results-for-fiscal-year-2021/ 2023-04-28T08:03:06+01:00 https://www.epigenomics.com/epigenomics-ag-reports-financial-results-for-the-first-quarter-of-2022/ 2023-04-28T08:03:06+01:00 https://www.epigenomics.com/%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8bepigenomics-ag-reports-financial-results-for-the-first-six-months-of-2022/ 2023-04-28T08:03:06+01:00 https://www.epigenomics.com/epigenomics-ag-places-maximum-number-of-mandatory-convertible-bonds-with-a-total-volume-of-eur-16-5-million/ 2023-04-28T08:03:07+01:00 https://www.epigenomics.com/epigenomics-ag-evp-of-finance-albert-weber-leaves-the-company/ 2023-04-28T08:03:07+01:00 https://www.epigenomics.com/%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8bepigenomics-ag-reports-financial-results-for-the-first-six-months-of-2021/ 2023-04-28T08:03:08+01:00 https://www.epigenomics.com/epigenomics-ag-securities-prospectus-for-the-issuance-of-a-mandatory-convertible-bond-in-the-amount-of-up-to-eur-16-5-million-approved-by-bafin/ 2023-04-28T08:03:08+01:00 https://www.epigenomics.com/%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8bnew-study-in-the-bmc-cancer-journal-shows-that-epi-procolonr-is-an-effective-method-to-increase-crc-screening-rates-in-medically-unders/ 2023-04-28T08:03:08+01:00 https://www.epigenomics.com/epigenomics-ag-plans-to-challenge-ncd-decision-and-unveils-its-next-generation-liquid-biopsy-test-for-colorectal-cancer-screening/ 2023-04-28T08:03:09+01:00 https://www.epigenomics.com/epigenomics-ag-dr-garces-transitions-to-company-advisor/ 2023-04-28T08:03:09+01:00 https://www.epigenomics.com/epigenomics-ag-reports-financial-results-for-fiscal-year-2020/ 2023-04-28T08:03:09+01:00 https://www.epigenomics.com/study-reported-in-bmc-gastroenterology-shows-significantly-better-performance-characteristics-of-epigenomics-liver-cancer-panel-compared-to-the-current-standard-of-care-for-the-early-detection-of-hcc/ 2023-04-28T08:03:09+01:00 https://www.epigenomics.com/%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8bepigenomics-ag-announces-conversion-result-of-the-first-conversion-period-of-the-mandatory-convertible-bond-2021-2024/ 2023-04-28T08:03:09+01:00 https://www.epigenomics.com/epigenomics-ag-decides-to-increase-share-capital-through-rights-issue-with-subscription-rights-of-existing-shareholders-3/ 2023-04-28T08:03:09+01:00 https://www.epigenomics.com/epigenomics-ag-reports-financial-results-for-the-first-quarter-of-2021/ 2023-04-28T08:03:09+01:00 https://www.epigenomics.com/new-study-published-in-the-journal-of-the-national-cancer-institute-concludes-that-epi-procolonr-is-the-test-of-choice-for-the-millions-of-individuals-not-willing-to-participate-in-fit-or-colonoscop/ 2023-04-28T08:03:10+01:00 https://www.epigenomics.com/epigenomics-ag-presents-operational-highlights-and-reports-financial-results-for-first-six-months-of-2020/ 2023-04-28T08:03:10+01:00 https://www.epigenomics.com/epigenomics-ag-cms-still-actively-working-on-proposed-decision-memo-with-goal-to-publish-as-soon-as-possible/ 2023-04-28T08:03:10+01:00 https://www.epigenomics.com/epigenomics-ag-hosts-conference-call-on-preliminary-cms-reimbursement-decision/ 2023-04-28T08:03:10+01:00 https://www.epigenomics.com/epigenomics-ag-notice-of-loss-pursuant-to-%c2%a7-92-par-1-aktg-6/ 2023-04-28T08:03:10+01:00 https://www.epigenomics.com/epigenomics-ag-reports-financial-results-for-the-first-nine-months-of-2020/ 2023-04-28T08:03:10+01:00 https://www.epigenomics.com/epigenomics-ag-epi-procolon-included-in-2020-national-comprehensive-cancer-network-colorectal-cancer-screening-guidelines/ 2023-04-28T08:03:11+01:00 https://www.epigenomics.com/epigenomics-ag-reports-financial-results-for-fiscal-year-2019-and-preliminary-unaudited-financial-results-for-the-first-quarter-of-2020/ 2023-04-28T08:03:11+01:00 https://www.epigenomics.com/epigenomics-ag-reports-2020-first-quarter-financial-results/ 2023-04-28T08:03:11+01:00 https://www.epigenomics.com/epigenomics-ag-to-participate-in-raymond-james-human-health-innovations-conference/ 2023-04-28T08:03:11+01:00 https://www.epigenomics.com/epigenomics-ag-reports-financial-results-for-the-first-nine-months-2019-2/ 2023-04-28T08:03:13+01:00 https://www.epigenomics.com/epigenomics-ag-new-micro-simulation-study-in-cancer-medicine-finds-epi-procolonr-provides-clinically-meaningful-reductions-in-incidence-and-mortality-of-colorectal-cancer/ 2023-04-28T08:03:13+01:00 https://www.epigenomics.com/epigenomics-ag-epigenomics-ag-reports-on-new-micro-simulation-study-results-published-in-cancer-medicine-indicating-that-epi-procolon-provides-clinically-meaningful-reductions-in-incidence-and-mortal/ 2023-04-28T08:03:13+01:00 https://www.epigenomics.com/centers-for-medicare-medicaid-services-open-ncd-review-process-for-epi-pro-colon/ 2023-04-28T08:03:13+01:00 https://www.epigenomics.com/epigenomics-announces-postponement-of-annual-general-meeting-due-to-coronavirus-and-preliminary-2019-flash-financial-results/ 2023-04-28T08:03:13+01:00 https://www.epigenomics.com/epigenomics-ag-implements-comprehensive-measures-to-reduce-costs-during-the-covid-19-pandemic-crisis/ 2023-04-28T08:03:13+01:00 https://www.epigenomics.com/epigenomics-ag-receives-medtech-outlooks-2019-top-10-in-vitro-diagnostics-award-3/ 2023-04-28T08:03:14+01:00 https://www.epigenomics.com/study-published-in-american-health-drug-benefits-suggests-that-non-invasive-screening-methods-including-epi-procolon-could-be-a-cost-effective-option-to-help-achieve-target-u-s-colorectal-cancer-sc/ 2023-04-28T08:03:14+01:00 https://www.epigenomics.com/epigenomics-ag-highlights-operational-achievements-and-reports-financial-results-for-first-six-months-2019-2/ 2023-04-28T08:03:14+01:00 https://www.epigenomics.com/epigenomics-ag-results-from-microsimulation-model-to-be-presented-at-renowned-health-conference-2/ 2023-04-28T08:03:14+01:00 https://www.epigenomics.com/epigenomics-ag-no-operational-reasons-for-sharp-decline-in-share-price-2/ 2023-04-28T08:03:14+01:00 https://www.epigenomics.com/epigenomics-ag-announces-conference-call-with-authors-presenting-at-the-european-public-health-conference-2/ 2023-04-28T08:03:14+01:00 https://www.epigenomics.com/epigenomics-ag-reports-results-for-financial-year-2018-2/ 2023-04-28T08:03:15+01:00 https://www.epigenomics.com/epigenomics-ag-cms-accepts-epigenomics-application-for-ncd-review/ 2023-04-28T08:03:15+01:00 https://www.epigenomics.com/epigenomics-ag-reports-2019-first-quarter-financial-results-2/ 2023-04-28T08:03:15+01:00 https://www.epigenomics.com/epigenomics-ag-epi-procolonr-receives-the-2019-excellence-in-molecular-diagnostics-award/ 2023-04-28T08:03:15+01:00 https://www.epigenomics.com/epigenomics-ag-new-report-shows-crc-screening-rates-increased-when-a-medically-underserved-population-is-offered-epi-procolonr-blood-test/ 2023-04-28T08:03:15+01:00 https://www.epigenomics.com/epigenomics-ag-to-participate-in-raymond-james-life-sciences-and-medtech-conference-in-june-2/ 2023-04-28T08:03:15+01:00 https://www.epigenomics.com/epigenomics-ag-new-clinical-data-support-the-utility-of-epi-procolonr-blood-test-for-colorectal-cancer-crc-screening-in-patients-with-lynch-syndrome-ls-the-most-common-hereditary-crc-syndrome/ 2023-04-28T08:03:15+01:00 https://www.epigenomics.com/correction-of-the-corporate-news-of-march-15-2019-1240-pm-epigenomics-ag-%e2%80%8bu-s-representatives-payne-and-marchant-introduce-bi-partisan-colorectal-cancer-detection-bill/ 2023-04-28T08:03:16+01:00 https://www.epigenomics.com/epigenomics-ag-announces-positive-results-from-microsimulation-model-2/ 2023-04-28T08:03:17+01:00 https://www.epigenomics.com/epigenomics-ag-u-s-representatives-payne-and-marchant-introduce-bi-partisan-colorectal-cancer-detection-bill/ 2023-04-28T08:03:17+01:00 https://www.epigenomics.com/epigenomics-ag-centers-for-medicare-medicaid-services-publish-final-rate-of-192-for-epigenomics-colorectal-cancer-screening-blood-test-epi-procolonr/ 2023-04-28T08:03:18+01:00 https://www.epigenomics.com/epigenomics-ag-obtains-ce-mark-for-liquid-biopsy-test-for-liver-cancer-detection-2/ 2023-04-28T08:03:18+01:00 https://www.epigenomics.com/epigenomics-ag-announces-veterans-administrations-adherence-study-using-epi-procolonr-colorectal-cancer-screening-blood-test/ 2023-04-28T08:03:18+01:00 https://www.epigenomics.com/epigenomics-ag-epigenomics-ag-announces-2018-third-quarter-and-nine-months-financial-results/ 2023-04-28T08:03:18+01:00 https://www.epigenomics.com/centers-for-medicare-medicaid-services-issue-official-2019-clinical-lab-fee-schedule-including-epi-procolonr/ 2023-04-28T08:03:18+01:00 https://www.epigenomics.com/epigenomics-ag-announces-initiation-of-a-prospective-clinical-study-for-liver-cancer-detection-2/ 2023-04-28T08:03:18+01:00 https://www.epigenomics.com/epigenomics-ag-centers-for-medicare-medicaid-services-publish-preliminary-rate-for-epigenomics-colorectal-cancer-screening-test-epi-procolonr/ 2023-04-28T08:03:19+01:00 https://www.epigenomics.com/epigenomics-ag-liquid-biopsy-test-for-liver-cancer-detection-to-obtain-ce-mark/ 2023-04-28T08:03:19+01:00 https://www.epigenomics.com/epigenomics-ag-announces-2018-second-quarter-and-six-month-financial-results-2/ 2023-04-28T08:03:19+01:00 https://www.epigenomics.com/epigenomics-ag-u-s-congress-supports-cms-coverage-of-colorectal-cancer-screening-blood-tests-2/ 2023-04-28T08:03:19+01:00 https://www.epigenomics.com/epigenomics-ag-capital-increase-through-rights-issue-with-subscription-rights-of-existing-shareholders-2/ 2023-04-28T08:03:19+01:00 https://www.epigenomics.com/supervisory-board-of-epigenomics-ag-appoints-albert-weber-as-executive-vice-president-finance-and-a-member-of-the-management-board-vorstand-2/ 2023-04-28T08:03:20+01:00 https://www.epigenomics.com/epigenomics-ag-gets-ce-ivd-mark-for-lung-cancer-test-epi-prolungr/ 2023-04-28T08:03:20+01:00 https://www.epigenomics.com/epigenomics-ag-u-s-senators-capito-and-heinrich-introduce-bi-partisan-colorectal-cancer-detection-bill/ 2023-04-28T08:03:20+01:00 https://www.epigenomics.com/epigenomics-ag-reports-results-for-financial-year-2017-2/ 2023-04-28T08:03:20+01:00 https://www.epigenomics.com/epigenomics-ag-blood-test-shows-promise-in-the-detection-of-liver-cancer-2/ 2023-04-28T08:03:20+01:00 https://www.epigenomics.com/epigenomics-ag-announces-2018-first-quarter-financial-results-2/ 2023-04-28T08:03:20+01:00 https://www.epigenomics.com/epigenomics-ag-announces-recent-payment-decision-by-cms-2/ 2023-04-28T08:03:21+01:00 https://www.epigenomics.com/epigenomics-ag-issues-convertible-bonds-2/ 2023-04-28T08:03:22+01:00 https://www.epigenomics.com/supervisory-board-of-epigenomics-ag-appoints-dr-jorge-garces-as-president-and-chief-scientific-officer-2/ 2023-04-28T08:03:22+01:00 https://www.epigenomics.com/epigenomics-ag-appointment-of-director-reimbursement-and-medical-affairs-2/ 2023-04-28T08:03:22+01:00 https://www.epigenomics.com/epigenomics-ag-announces-2017-third-quarter-and-nine-months-financial-results-2/ 2023-04-28T08:03:22+01:00 https://www.epigenomics.com/epigenomics-ag-offer-document-published-for-the-voluntary-public-takeover-offer-for-epigenomics-ag/ 2023-04-28T08:03:23+01:00 https://www.epigenomics.com/epigenomics-ag-executive-board-and-supervisory-board-recommend-acceptance-of-the-voluntary-public-takeover-offer-2/ 2023-04-28T08:03:23+01:00 https://www.epigenomics.com/epigenomics-ag-voluntary-public-takeover-offer-by-summit-hero-holding-not-successful/ 2023-04-28T08:03:23+01:00 https://www.epigenomics.com/epigenomics-ag-announces-2017-second-quarter-and-six-months-financial-results-2/ 2023-04-28T08:03:23+01:00 https://www.epigenomics.com/epigenomics-commences-post-approval-study-on-epi-procolonr/ 2023-04-28T08:03:23+01:00 https://www.epigenomics.com/epigenomics-ag-journal-of-molecular-diagnosis-therapy-publishes-review-of-blood-based-screening-test-epi-procolonr-2-0-ce/ 2023-04-28T08:03:24+01:00 https://www.epigenomics.com/epigenomics-joins-forces-with-hundreds-of-organizations-to-increase-colorectal-cancer-screening-rates-in-the-united-states-2/ 2023-04-28T08:03:24+01:00 https://www.epigenomics.com/epigenomics-ag-u-s-department-of-veterans-affairs-awards-supply-contract-for-epi-procolonr/ 2023-04-28T08:03:24+01:00 https://www.epigenomics.com/epigenomics-ag-reports-results-for-financial-year-2016/ 2023-04-28T08:03:24+01:00 https://www.epigenomics.com/epigenomics-ag-blitz-f16-83-gmbh-to-launch-takeover-offer-for-epigenomics-ag/ 2023-04-28T08:03:24+01:00 https://www.epigenomics.com/epigenomics-ag-announces-2017-first-quarter-financial-results-2/ 2023-04-28T08:03:24+01:00 https://www.epigenomics.com/epigenomics-ag-journal-of-the-american-medical-association-jama-publishes-letter-to-the-editor-that-clarifies-clinical-performance-data-for-epi-procolonr/ 2023-04-28T08:03:25+01:00 https://www.epigenomics.com/epigenomics-ag-arup-laboratories-to-offer-epi-procolonr-epigenomics-blood-based-colorectal-cancer-screening-test/ 2023-04-28T08:03:25+01:00 https://www.epigenomics.com/epigenomics-ag-announces-2016-third-quarter-and-nine-months-financial-results-and-reports-on-operational-highlights-2/ 2023-04-28T08:03:25+01:00 https://www.epigenomics.com/epigenomics-ag-to-participate-in-investor-conferences-2/ 2023-04-28T08:03:25+01:00 https://www.epigenomics.com/epigenomics-ag-journal-of-cancer-treatment-and-research-communications-publishes-results-of-study-with-blood-test-epi-procolonr/ 2023-04-28T08:03:25+01:00 https://www.epigenomics.com/congressman-donald-m-payne-jr-introduces-bipartisan-2016-colorectal-cancer-detection-act-2/ 2023-04-28T08:03:26+01:00 https://www.epigenomics.com/epigenomics-ag-china-fda-names-epigenomics-blood-based-septin9-colorectal-cancer-test-a-most-innovative-medical-product-for-2015/ 2023-04-28T08:03:27+01:00 https://www.epigenomics.com/labcorp-is-first-u-s-laboratory-network-to-offer-epigenomics-epi-pro-colonr-colorectal-cancer-screening-test-nationally-available-immediately/ 2023-04-28T08:03:27+01:00 https://www.epigenomics.com/epigenomics-ag-announces-2016-first-quarter-financial-results-and-reports-on-operational-highlights/ 2023-04-28T08:03:27+01:00 https://www.epigenomics.com/epigenomics-epi-procolonr-included-in-newly-issued-uspstf-guidelines-for-colorectal-cancer-screening/ 2023-04-28T08:03:27+01:00 https://www.epigenomics.com/epigenomics-ag-announces-2016-second-quarter-and-six-months-financial-results-and-reports-on-operational-highlights-2/ 2023-04-28T08:03:27+01:00 https://www.epigenomics.com/epigenomics-ag-confidentially-submits-draft-registration-statement-for-potential-u-s-public-offering-of-adss/ 2023-04-28T08:03:27+01:00 https://www.epigenomics.com/epigenomics-ag-announces-2015-third-quarter-and-nine-month-financial-results-and-reports-on-operational-highlights-2/ 2023-04-28T08:03:28+01:00 https://www.epigenomics.com/epigenomics-ag-bondholders-resolve-on-amendment-of-the-terms-and-conditions-of-the-2013-convertible-bonds-2/ 2023-04-28T08:03:28+01:00 https://www.epigenomics.com/epigenomics-ag-reports-results-for-the-financial-year-ended-december-31-2015-and-provides-outlook-for-2016-2/ 2023-04-28T08:03:28+01:00 https://www.epigenomics.com/epigenomics-ag-epigenomics-enters-strategic-license-and-development-agreement-with-biochain-on-novel-blood-based-lung-cancer-test/ 2023-04-28T08:03:28+01:00 https://www.epigenomics.com/epigenomics-ag-epigenomics-to-present-data-on-novel-blood-based-test-for-the-detection-of-lung-cancer-at-aacr-annual-meeting-2016/ 2023-04-28T08:03:28+01:00 https://www.epigenomics.com/epigenomics-announces-commercial-launch-of-epi-procolonr-in-the-u-s/ 2023-04-28T08:03:28+01:00 https://www.epigenomics.com/epigenomics-ag-epigenomics-ag-successfully-completes-capital-increase/ 2023-04-28T08:03:29+01:00 https://www.epigenomics.com/epigenomics-ag-epigenomics-and-biochain-announce-the-inclusion-of-their-proprietary-blood-based-septin9-test-in-the-chinese-screening-guideline-for-colorectal-cancer/ 2023-04-28T08:03:29+01:00 https://www.epigenomics.com/epigenomics-ag-epigenomics-ag-announces-q2-2015-and-6m-2015-financial-results-and-reports-on-operational-highlights/ 2023-04-28T08:03:29+01:00 https://www.epigenomics.com/epigenomics-ag-epigenomics-ag-to-provide-an-update-on-blood-based-epigenetic-tests-at-the-association-of-molecular-pathology-amp-2015-annual-meeting/ 2023-04-28T08:03:29+01:00 https://www.epigenomics.com/epigenomics-ag-fda-requests-further-data-for-approval-of-epigenomics-blood-based-colorectal-cancer-screening-test/ 2023-04-28T08:03:29+01:00 https://www.epigenomics.com/epigenomics-ag-novel-panel-of-blood-based-dna-methylation-biomarkers-shows-promising-results-in-the-detection-of-lung-cancer-2/ 2023-04-28T08:03:29+01:00 https://www.epigenomics.com/epigenomics-ag-announces-q1-2015-financial-results-and-reports-on-operational-highlights/ 2023-04-28T08:03:30+01:00 https://www.epigenomics.com/epigenomics-ag-epigenomics-ag-reports-results-for-the-financial-year-ended-december-31-2014-and-provides-outlook-for-2015/ 2023-04-28T08:03:31+01:00 https://www.epigenomics.com/epigenomics-receives-eur-2-8m-grant-for-validation-of-lung-cancer-biomarkers-in-blood-plasma-2/ 2023-04-28T08:03:31+01:00 https://www.epigenomics.com/epigenomics-reaches-99-5-adherence-for-epi-procolonr-in-admit-study/ 2023-04-28T08:03:31+01:00 https://www.epigenomics.com/epigenomics-ag-epigenomics-strategic-commercialization-partner-polymedco-reiterates-its-commitment-to-support-epi-procolonr-in-the-united-states/ 2023-04-28T08:03:32+01:00 https://www.epigenomics.com/epigenomics-ag-epigenomics-ag-announces-2014-third-quarter-and-nine-month-financial-results-and-reports-on-operational-highlights/ 2023-04-28T08:03:32+01:00 https://www.epigenomics.com/epigenomics-ag-epigenomics-and-biochain-announce-approval-of-epi-procolonr-in-china/ 2023-04-28T08:03:32+01:00 https://www.epigenomics.com/epigenomics-ag-epigenomics-to-present-at-the-oppenheimer-25th-annual-healthcare-conference/ 2023-04-28T08:03:32+01:00 https://www.epigenomics.com/epigenomics-ag-first-patients-enrolled-in-epigenomics-epi-procolonr-admit-study/ 2023-04-28T08:03:32+01:00 https://www.epigenomics.com/epigenomics-ag-epigenomics-announces-completion-of-enrollment-in-epi-procolonr-admit-trial/ 2023-04-28T08:03:32+01:00 https://www.epigenomics.com/epigenomics-ag-provides-update-on-regulatory-status-and-information-on-additional-clinical-study-for-epi-procolonr-in-the-u-s/ 2023-04-28T08:03:33+01:00 https://www.epigenomics.com/epigenomics-ag-epigenomics-ag-announces-h1-2014-and-q2-2014-financial-results-and-reports-on-operational-highlights/ 2023-04-28T08:03:33+01:00 https://www.epigenomics.com/epigenomics-ag-epigenomics-ag-converts-to-registered-shares/ 2023-04-28T08:03:33+01:00 https://www.epigenomics.com/epigenomics-ag-epigenomics-provides-corporate-update/ 2023-04-28T08:03:33+01:00 https://www.epigenomics.com/epigenomics-ag-epigenomics-ag-raises-usd-5-3-million-from-its-strategic-commercialization-partner-biochain/ 2023-04-28T08:03:33+01:00 https://www.epigenomics.com/epigenomics-ag-results-of-adherence-study-published-in-bmc-gastroenterology-demonstrate-that-epigenomics-blood-based-epi-procolonr-improves-compliance-to-crc-screening/ 2023-04-28T08:03:33+01:00 https://www.epigenomics.com/epigenomics-ag-epigenomics-partner-biochain-successfully-completes-clinical-validation-study-for-cfda-approval-of-epi-procolonr-in-china/ 2023-04-28T08:03:34+01:00 https://www.epigenomics.com/epigenomics-ag-epigenomics-updates-on-regulatory-status-for-epi-procolonr-in-the-u-s-a/ 2023-04-28T08:03:34+01:00 https://www.epigenomics.com/epigenomics-ag-epigenomics-ag-announces-q1-2014-financial-results-and-reports-on-operational-highlights/ 2023-04-28T08:03:34+01:00 https://www.epigenomics.com/epigenomics-ag-fda-issues-response-letter-for-epigenomics-colorectal-cancer-screening-blood-test-epi-procolonr-requesting-further-data-pre-approval/ 2023-04-28T08:03:34+01:00 https://www.epigenomics.com/epigenomics-ag-epigenomics-ag-announces-publication-of-results-of-two-u-s-clinical-studies-with-its-blood-based-epi-procolonr-crc-screening-test/ 2023-04-28T08:03:34+01:00 https://www.epigenomics.com/epigenomics-ag-epigenomics-ag-reports-preliminary-results-and-highlights-for-the-year-ended-december-31-2013/ 2023-04-28T08:03:36+01:00 https://www.epigenomics.com/epigenomics-ag-clinical-study-conducted-in-the-czech-republic-confirms-blood-based-septin9-test-to-be-an-attractive-alternative-for-crc-screening-programs-2/ 2023-04-28T08:03:36+01:00 https://www.epigenomics.com/epigenomics-and-vsa-receive-approval-to-market-epi-procolon-in-argentina-2/ 2023-04-28T08:03:36+01:00 https://www.epigenomics.com/epigenomics-ag-fda-advisory-committee-provides-recommendations-for-epigenomics-colorectal-cancer-screening-blood-test-3/ 2023-04-28T08:03:36+01:00 https://www.epigenomics.com/epigenomics-ag-epigenomics-ag-publishes-2013-annual-report-and-provides-outlook-for-the-year-2014/ 2023-04-28T08:03:36+01:00 https://www.epigenomics.com/epigenomics-ag-epigenomics-ag-secures-additional-financing/ 2023-04-28T08:03:37+01:00 https://www.epigenomics.com/epigenomics-ag-epigenomics-ag-welcomes-reimbursement-for-septin9-testing-by-french-insurance-provider/ 2023-04-28T08:03:37+01:00 https://www.epigenomics.com/epigenomics-ag-epigenomics-signs-licensing-and-supply-agreement-with-kindstar-for-epi-prolung-in-china/ 2023-04-28T08:03:37+01:00 https://www.epigenomics.com/epigenomics-ag-epigenomics-begins-trading-on-otcqx-marketplace-in-the-u-s/ 2023-04-28T08:03:37+01:00 https://www.epigenomics.com/epigenomics-ag-epigenomics-announces-date-for-the-fda-advisory-committee-meeting-to-review-epi-procolon-and-for-the-publication-of-preliminary-financial-results-2013/ 2023-04-28T08:03:37+01:00 https://www.epigenomics.com/epigenomics-ag-epigenomics-further-strengthens-intellectual-property-coverage-for-epi-procolon-in-the-u-s-and-in-china/ 2023-04-28T08:03:37+01:00 https://www.epigenomics.com/epigenomics-ag-epigenomics-ag-secures-financing-of-up-to-eur-5m/ 2023-04-28T08:03:38+01:00 https://www.epigenomics.com/epigenomics-ag-epigenomics-signs-joint-commercialization-agreement-for-epi-procolonr-in-north-america-with-polymedco/ 2023-04-28T08:03:38+01:00 https://www.epigenomics.com/epigenomics-ag-epigenomics-and-biochain-enter-into-broad-strategic-collaboration-in-china-and-investment-into-epigenomics/ 2023-04-28T08:03:38+01:00 https://www.epigenomics.com/epigenomics-ag-epigenomics-ag-announces-2013-third-quarter-and-nine-month-financial-results-and-reports-on-operational-highlights/ 2023-04-28T08:03:38+01:00 https://www.epigenomics.com/epigenomics-ag-epigenomics-methylated-shox2-biomarker-shows-promising-results-for-therapy-monitoring-of-lung-cancer-patients/ 2023-04-28T08:03:38+01:00 https://www.epigenomics.com/epigenomics-ag-epigenomics-ag-announces-fda-advisory-committee-meeting-to-review-epi-procolonr/ 2023-04-28T08:03:38+01:00 https://www.epigenomics.com/epigenomics-ag-epigenomics-establishes-american-depositary-receipt-adr-program/ 2023-04-28T08:03:39+01:00 https://www.epigenomics.com/epigenomics-us-study-suggests-blood-based-septin9-crc-screening-could-save-lives-and-be-health-economically-beneficial-2/ 2023-04-28T08:03:39+01:00 https://www.epigenomics.com/epigenomics-ag-epigenomics-ag-announces-h1-2013-and-q2-2013-financial-results-and-reports-on-operational-highlights/ 2023-04-28T08:03:39+01:00 https://www.epigenomics.com/epigenomics-ag-results-of-comparative-study-between-epigenomics-epi-procolonr-and-fit-to-be-presented-at-digestive-disease-week/ 2023-04-28T08:03:40+01:00 https://www.epigenomics.com/epigenomics-ag-epigenomics-ag-announces-q1-2013-financial-results-and-reports-on-operational-highlights/ 2023-04-28T08:03:41+01:00 https://www.epigenomics.com/epigenomics-ag-changes-in-the-management-2/ 2023-05-18T23:00:00+01:00 https://www.epigenomics.com/de/epigenomics-ag-veranderungen-im-vorstand/ 2023-05-18T23:00:00+01:00 https://www.epigenomics.com/de/epigenomics-ag-rucktritt-des-vorstandsmitglieds-und-chief-scientific-officers-dr-andrew-lukowiak/ 2023-05-18T23:00:00+01:00 https://www.epigenomics.com/epigenomics-ag-member-of-the-executive-board-and-chief-scientific-officer-andrew-lukowiak-resigns/ 2023-05-18T23:00:00+01:00 https://www.epigenomics.com/de/%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8bepigenomics-ag-veroffentlicht-finanzergebnisse-fur-das-erste-quartal-2023/ 2023-05-30T23:00:00+01:00 https://www.epigenomics.com/%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8bepigenomics-ag-reports-financial-results-for-the-first-quarter-of-2023/ 2023-05-30T23:00:00+01:00 https://www.epigenomics.com/de/epigenomics-ag-%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8b%e2%80%8bverhandlungen-uber-den-erwerb-nahezu-samtlicher-vermogenswerte/ 2023-06-11T23:00:00+01:00 https://www.epigenomics.com/epigenomics-ag-negotiations-on-the-acquisitions-of-almost-all-assets/ 2023-06-11T23:00:00+01:00 https://www.epigenomics.com/epigenomics-ag-agreement-on-the-acquisition-of-almost-all-assets/ 2023-07-23T23:00:00+01:00 https://www.epigenomics.com/de/epigenomics-ag-vertragsschluss-uber-den-erwerb-nahezu-samtlicher-vermogenswerte/ 2023-07-23T23:00:00+01:00 https://www.epigenomics.com/epigenomics-ag-announces-successful-agreement-on-the-acquisition-of-significant-assets/ 2023-07-23T23:00:00+01:00 https://www.epigenomics.com/de/epigenomics-ag-verkundet-erfolgreichen-vertragsabschluss-uber-den-erwerb-wesentlicher-vermogenswerte/ 2023-07-23T23:00:00+01:00 https://www.epigenomics.com/epigenomics-ag-capital-reduction-planned-at-a-ratio-of-5-1/ 2023-08-01T23:00:00+01:00 https://www.epigenomics.com/de/epigenomics-ag-kapitalherabsetzung-im-verhaltnis-von-5-1-geplant/ 2023-08-01T23:00:00+01:00 https://www.epigenomics.com/de/epigenomics-ag-veroffentlicht-finanzergebnisse-fur-die-ersten-sechs-monate-2023/ 2023-08-09T23:00:00+01:00 https://www.epigenomics.com/epigenomics-ag-publishes-financial-results-for-the-first-six-months-2023/ 2023-08-09T23:00:00+01:00 https://www.epigenomics.com/epigenomics-ag-pareto-and-warburg-publish-analyst-research-reports/ 2023-09-04T23:00:00+01:00 https://www.epigenomics.com/de/epigenomics-ag-pareto-und-warburg-veroffentlichen-analysten-researchs/ 2023-09-04T23:00:00+01:00 https://www.epigenomics.com/de/epigenomics-ag-veroffentlichung-gemas-%c2%a7-40-abs-1-wphg-mit-dem-ziel-der-europaweiten-verbreitung-47/ 2023-09-04T23:00:00+01:00 https://www.epigenomics.com/de/epigenomics-ag-zustimmung-der-hauptversammlung-uber-den-erwerb-nahezu-samtlicher-vermogenswerte-und-entsprechende-anderung-des-satzungsmasigen-unternehmensgegenstands/ 2023-09-10T23:00:00+01:00 https://www.epigenomics.com/epigenomics-ag-approval-by-the-extraordinary-general-meeting-of-the-acquisition-of-almost-all-assets-and-corresponding-change-of-the-statutory-purpose-of-the-company/ 2023-09-10T23:00:00+01:00 https://www.epigenomics.com/epigenomics-ag-closing-of-agreement-on-the-acquisition-of-almost-all-assets-and-adjustment-of-guidance-for-2023/ 2023-10-09T23:00:00+01:00 https://www.epigenomics.com/de/epigenomics-ag-vollzug-des-vertrags-uber-die-verauserung-nahezu-samtlicher-vermogenswerte-der-gesellschaft-und-anpassung-der-prognose-fur-2023/ 2023-10-09T23:00:00+01:00 https://www.epigenomics.com/de/epigenomics-ag-verkundet-vollzug-des-vertrags-uber-die-verauserung-nahezu-samtlicher-vermogenswerte-der-gesellschaft-und-anpassung-der-prognose-fur-2023/ 2023-10-09T23:00:00+01:00 https://www.epigenomics.com/epigenomics-ag-announces-closing-of-agreement-on-the-acquisition-of-almost-all-of-the-companys-assets-and-adjustment-of-guidance-for-2023/ 2023-10-09T23:00:00+01:00 https://www.epigenomics.com/epigenomics-ag-release-according-to-article-41-of-the-wphg-the-german-securities-trading-act-with-the-objective-of-europe-wide-distribution-15/ 2023-10-18T14:34:10+01:00 https://www.epigenomics.com/de/epigenomics-ag-veroeffentlichung-der-gesamtzahl-der-stimmrechte-nach-%c2%a7-41-wphg-mit-dem-ziel-der-europaweiten-verbreitung-5/ 2023-10-18T14:35:26+01:00 https://www.epigenomics.com/de/epigenomics-ag-veroeffentlichung-der-gesamtzahl-der-stimmrechte-nach-%c2%a7-41-wphg-mit-dem-ziel-der-europaweiten-verbreitung-6/ 2023-10-27T13:47:33+01:00 https://www.epigenomics.com/epigenomics-ag-release-according-to-article-41-of-the-wphg-the-german-securities-trading-act-with-the-objective-of-europe-wide-distribution-16/ 2023-10-27T13:47:50+01:00 https://www.epigenomics.com/epigenomics-ag-executive-board-member-jens-ravens-leaves-the-company-on-april-30-2024/ 2023-10-29T22:00:00+00:00 https://www.epigenomics.com/de/epigenomics-ag-ausscheiden-des-vorstands-jens-ravens-zum-30-april-2024/ 2023-11-06T09:19:50+00:00 https://www.epigenomics.com/de/epigenomics-ag-veroeffentlichung-der-gesamtzahl-der-stimmrechte-nach-%c2%a7-41-wphg-mit-dem-ziel-der-europaweiten-verbreitung-7/ 2023-11-22T11:15:06+00:00 https://www.epigenomics.com/epigenomics-ag-release-according-to-article-41-of-the-wphg-the-german-securities-trading-act-with-the-objective-of-europe-wide-distribution-17/ 2023-11-22T11:15:20+00:00 https://www.epigenomics.com/de/herabsetzung-des-grundkapitals-nach-den-vorschriften-ueber-die-ordentliche-kapitalherabsetzung-gemaess-%c2%a7-222-ff-aktg-durch-zusammenlegung-von-aktien-und-umstellung-der-boersennotierung/ 2023-11-30T21:06:24+00:00 https://www.epigenomics.com/de/epigenomics-ag-amtsniederlegung-des-aufsichtsratsmitglieds-dr-heikki-lanckriet-phd/ 2024-01-25T22:00:00+00:00 https://www.epigenomics.com/epigenomics-ag-resignation-of-supervisory-board-member-dr-heikki-lanckriet-phd/ 2024-01-25T22:00:00+00:00 https://www.epigenomics.com/epigenomics-ag-supervisory-board-of-epigenomics-ag-appoints-hansjorg-plaggemars-as-member-of-the-executive-board/ 2024-01-30T22:00:00+00:00 https://www.epigenomics.com/de/epigenomics-ag-aufsichtsrat-der-epigenomics-ag-beruft-hansjorg-plaggemars-als-vorstand/ 2024-01-30T22:00:00+00:00 https://www.epigenomics.com/de/epigenomics-ag-jochen-hummel-fur-heikki-lanckriet-in-den-aufsichtsrat-bestellt/ 2024-02-14T22:00:00+00:00 https://www.epigenomics.com/epigenomics-ag-jochen-hummel-appointed-to-the-supervisory-board-to-replace-heikki-lanckriet/ 2024-02-14T22:00:00+00:00 https://www.epigenomics.com/de/epigenomics-ag-vorabbekanntmachung-ueber-die-veroeffentlichung-von-finanzberichten-gemaess-%c2%a7-114-115-117-wphg-2/ 2024-03-06T13:17:36+00:00 https://www.epigenomics.com/epigenomics-ag-preliminary-announcement-of-the-publication-of-financial-reports-according-to-articles-114-115-117-of-the-wphg-the-german-securities-act-2/ 2024-03-06T13:20:22+00:00 https://www.epigenomics.com/de/epigenomics-ag-veroeffentlichung-der-gesamtzahl-der-stimmrechte-nach-%c2%a7-41-wphg-mit-dem-ziel-der-europaweiten-verbreitung-8/ 2024-03-13T19:29:49+00:00 https://www.epigenomics.com/epigenomics-ag-release-according-to-article-41-of-the-wphg-the-german-securities-trading-act-with-the-objective-of-europe-wide-distribution-18/ 2024-03-13T19:30:53+00:00 https://www.epigenomics.com/de/epigenomics-ag-veroffentlicht-finanzergebnisse-fur-das-geschaftsjahr-2023/ 2024-03-13T22:00:00+00:00 https://www.epigenomics.com/epigenomics-ag-publishes-financial-results-for-fiscal-year-2023/ 2024-03-13T22:00:00+00:00 https://www.epigenomics.com/de/epigenomics-ag-veroeffentlichung-der-gesamtzahl-der-stimmrechte-nach-%c2%a7-41-wphg-mit-dem-ziel-der-europaweiten-verbreitung-9/ 2024-04-10T18:10:40+01:00 https://www.epigenomics.com/epigenomics-ag-release-according-to-article-41-of-the-wphg-the-german-securities-trading-act-with-the-objective-of-europe-wide-distribution-19/ 2024-04-10T18:11:30+01:00 https://www.epigenomics.com/de/epigenomics-ag-ausscheiden-des-vorstands-jens-ravens-zum-30-april-2024-2/ 2024-04-29T23:00:00+01:00 https://www.epigenomics.com/epigenomics-ag-executive-board-member-jens-ravens-leaves-the-company-on-april-30-2024-2/ 2024-04-29T23:00:00+01:00 https://www.epigenomics.com/epigenomics-ag-release-according-to-article-41-of-the-wphg-the-german-securities-trading-act-with-the-objective-of-europe-wide-distribution-19/ 2024-07-18T13:10:28+01:00 https://www.epigenomics.com/de/epigenomics-ag-veroeffentlichung-der-gesamtzahl-der-stimmrechte-nach-%c2%a7-41-wphg-mit-dem-ziel-der-europaweiten-verbreitung-9-2/ 2024-07-18T13:12:13+01:00 https://www.epigenomics.com/de/vorlaeufiges-halbjahresergebnis-zum-30-juni-2024/ 2024-07-29T07:43:44+01:00 https://www.epigenomics.com/epigenomics-ag-preliminary-half-year-results-as-at-june-30-2024/ 2024-07-29T07:45:11+01:00 https://www.epigenomics.com/epigenomics-ag-preliminary-announcement-of-the-publication-of-financial-reports-according-to-articles-114-115-117-of-the-wphg-the-german-securities-act-2-2/ 2024-07-29T14:45:42+01:00 https://www.epigenomics.com/de/epigenomics-ag-vorabbekanntmachung-ueber-die-veroeffentlichung-von-finanzberichten-gemaess-%c2%a7-114-115-117-wphg-2-2/ 2024-07-29T14:47:20+01:00 https://www.epigenomics.com/de/epigenomics-ag-vorlaeufiges-jahresergebnis-zum-31-dezember-2024/ 2025-01-21T14:09:16+00:00 https://www.epigenomics.com/epigenomics-ag-preliminary-annual-results-as-of-december-31-2024/ 2025-01-21T14:12:18+00:00 https://www.epigenomics.com/epigenomics-ag-annual-result-as-at-december-31-2024-and-forecast-deviation/ 2025-04-23T10:33:38+01:00 https://www.epigenomics.com/de/epigenomics-ag-jahresergebnis-zum-31-dezember-2024-und-prognoseabweichung/ 2025-04-23T10:34:12+01:00 https://www.epigenomics.com/de/epigenomics-ag-vorabbekanntmachung-ueber-die-veroeffentlichung-von-finanzberichten-gemaess-%c2%a7-114-115-117-wphg-2-3/ 2025-04-28T09:33:42+01:00 https://www.epigenomics.com/epigenomics-ag-preliminary-announcement-of-the-publication-of-financial-reports-according-to-articles-114-115-117-of-the-wphg-the-german-securities-act-2-3/ 2025-04-28T09:40:14+01:00 https://www.epigenomics.com/de/epigenomics-ag-veroeffentlichung-gemaess-%c2%a7-40-abs-1-wphg/ 2025-06-13T12:17:56+01:00 https://www.epigenomics.com/epigenomics-ag-veroffentlichung-nach-%c2%a7-40-abs-1-wphg/ 2025-06-13T12:19:32+01:00 https://www.epigenomics.com/de/epigenomics-ag-vorlaeufiges-halbjahresergebnis-zum-30-juni-2025/ 2025-07-10T16:12:09+01:00 https://www.epigenomics.com/epigenomics-ag-preliminary-half-year-results-as-of-june-30-2025/ 2025-07-10T16:14:31+01:00 https://www.epigenomics.com/de/epigenomics-ag-vorabbekanntmachung-ueber-die-veroeffentlichung-von-finanzberichten-gemaess-%c2%a7-114-115-117-wphg-3/ 2025-07-21T11:36:39+01:00 https://www.epigenomics.com/epigenomics-ag-preliminary-announcement-of-the-publication-of-financial-reports-according-to-articles-114-115-117-of-the-wphg-the-german-securities-act-3/ 2025-07-21T12:02:42+01:00 https://www.epigenomics.com/epigenomics-ag-preliminary-half-year-results-as-of-june-30-2025-2/ 2026-01-19T16:26:38+00:00 https://www.epigenomics.com/de/epigenomics-ag-vorlaeufiges-halbjahresergebnis-zum-30-juni-2025-2/ 2026-01-19T16:27:25+00:00 https://www.epigenomics.com/de/epigenomics-ag-vorabbekanntmachung-ueber-die-veroeffentlichung-von-finanzberichten-gemaess-%c2%a7-114-115-117-wphg-3-2/ 2026-04-01T12:56:44+01:00 https://www.epigenomics.com/epigenomics-ag-preliminary-announcement-of-the-publication-of-financial-reports-according-to-articles-114-115-117-of-the-wphg-the-german-securities-act-3-2/ 2026-04-01T12:57:12+01:00 https://www.epigenomics.com/de/epigenomics-ag-durchfuehrung-der-kapitalerhoehung-in-hoehe-von-bis-zu-eur-219-24400-durch-ausgabe-von-bis-zu-219-244-neuen-aktien/ 2026-07-03T09:05:59+01:00 https://www.epigenomics.com/epigenomics-ag-completion-of-a-capital-increase-of-up-to-eur-219244-00-through-the-issuance-of-up-to-219244-new-shares/ 2026-07-03T09:07:18+01:00 https://www.epigenomics.com/de/epigenomics-ag-vorlaufiges-halbjahresergebnis-zum-30-juni-2026/ 2026-07-20T13:28:57+01:00 https://www.epigenomics.com/epigenomics-ag-preliminary-half-year-results-as-of-june-30-2026/ 2026-07-20T13:29:32+01:00